MedAssets (MDAS +19%) pops after its Q3 shreds Street EPS estimates. Net revenue rose 50% Y/Y,...
MedAssets (MDAS +19%) pops after its Q3 shreds Street EPS estimates. Net revenue rose 50% Y/Y, primarily due to a lower tax rate and write-downs related to its 2010 acquisition of Broadlane. Oppenheimer and Morgan Stanley both issue positive comments after the results, reiterating their Outperform and Overwieght ratings on the shares (I, II).
From other sites
Video at CNBC.com (Oct 31, 2013)
Video at CNBC.com (Oct 3, 2013)
at CNBC.com (Oct 27, 2011)
at CNBC.com (Mar 26, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs